Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Brough

Showing results (21-30 of 22) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 22 results.
Nature Communications|November 5, 2024
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancerM T Herrera-Abreu, J Guan, U Khalid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2024
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancerE Harvey-Jones, M Raghunandan, L Robbez-Masson, et al.
Pageof 3

Showing results (21-30 of 22) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 22 results.
Nature Communications|November 5, 2024
Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancerM T Herrera-Abreu, J Guan, U Khalid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2024
Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancerE Harvey-Jones, M Raghunandan, L Robbez-Masson, et al.
Pageof 3